Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
73
-
Total 13F shares, excl. options
-
41.4M
-
Shares change
-
-1.89M
-
Total reported value, excl. options
-
$72.9M
-
Value change
-
-$1.83M
-
Put/Call ratio
-
0.44
-
Number of buys
-
30
-
Number of sells
-
-50
-
Price
-
$1.76
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q3 2024
103 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q3 2024.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 73 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.4M shares
of 54.7M outstanding shares and own 75.57% of the company stock.
Largest 10 shareholders include SUVRETTA CAPITAL MANAGEMENT, LLC (5.07M shares), FRANKLIN RESOURCES INC (4.71M shares), TANG CAPITAL MANAGEMENT LLC (4.7M shares), Sofinnova Investments, Inc. (4.39M shares), VANGUARD GROUP INC (2.8M shares), Bain Capital Life Sciences Investors, LLC (2.69M shares), abrdn plc (2.66M shares), Bleichroeder LP (1.87M shares), BlackRock, Inc. (1.86M shares), and Woodline Partners LP (1.26M shares).
This table shows the top 73 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.